Community Practice

Latest News


CME Content


USP created the Pharmaceutical Ingredient Verification Program in response to increasing concerns throughout the industry about the quality and consistency of pharmaceutical ingredients.

A measure to expand Oregon?s prescription drug discount program to allow small businesses and labor unions to buy medicine for their employees through the program was signed into law by Gov. Ted Kulongoski.

Workers' compensation claims processor WorkingRx and Jopari Solutions, a developer of electronic billing systems, have implemented an end-to-end system for the electronic processing of pharmacy workers? compensations bills.

DEA plans to make N-phenethyl-4-piperidone (NPP) a List I chemical in an effort to control the illicit manufacture of fentanyl, a schedule II controlled substance.

Beginning on April 30, participating members have been able to more effectively manage the performance programs from seven more drug- companies, including ReoPro (abciximab) from Eli Lilly and Integrilin (eptifibatide) from Schering.

XLHealth Corp. is adding medication therapy management to its Care Improvement Plus Medicare Advantage plan in Arkansas, Georgia, Maryland, Missouri, South Carolina, and Texas.

American consumers currently have access to nearly 59,000 retail pharmacies widely dispersed in urban, suburban, and rural areas throughout the country, giving them, on average, access to 21 competing pharmacies located near their current pharmacy.

The FDA is requesting an update to the existing black box to include information regarding the risk of suicidal thinking and behavior in young adults ages 18 to 24 years old during the first two months of treatment.

Patients with von Willebrand disease (vWD) undergoing surgery may now benefit from the use of Humate-P (Antihemophilic Factor/von Willebrand Factor Complex) to prevent excessive bleeding during and after surgery.

Long-acting Lantus (insulin glargine, Sanofi-Aventis) will soon be available in a device that will allow diabetes patients to administer up to 80 units in one injection.

The FDA has approved the use of estrogen for the treatment of moderate to severe vaginal dryness and pain with intercourse and for symptoms of vulvar and vaginal atrophy associated with menopause.